Simple blood test may spot High-Risk heart patients after bypass

NCT ID NCT07480915

Recruiting now Knowledge-focused Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 160 heart failure patients who are scheduled for coronary artery bypass surgery. Researchers want to see if measuring a substance called GDF-15 in the blood before surgery can help predict who will have serious heart problems in the next year. The study does not test any new treatment—it only observes and collects data to improve risk assessment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a simple blood test to identify heart failure patients at highest risk after bypass surgery, helping doctors monitor them more closely.
What could go wrong: This is an observational study, not a treatment trial. It only measures a biomarker (GDF-15) and does not test any new drug or therapy. The results may not change current care or apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CABG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CABG CAD - CORONARY ARTERY DISEASE HEART FAILURE

Contacts and locations

Locations

Cardiology Research Institute, Tomsk National Research Medical Center Russian Academy of Sciences
RECRUITING

Tomsk, Tomsk Oblast, 634050, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.